摘要: Myelodysplastic syndromes (MDS) are clonal diseases of the elderly characterized by chronic cytopenias, dysplasia and a variable risk progression to acute myeloid leukemia (AML). Aberrant methylation tumor-suppressor gene promoters has been established for many years recently tracked most immature cells MDS, suggesting that these alterations drivers MDS pathogenesis. In recent years, recurrent somatic mutations in genes encoding proteins involved DNA demethylation covalent histone modifications have reported malignancies, including MDS. Whole-genome epigenetic profiles also emerging. parallel with advances molecular pathogenesis clinical trials hypomethylating agents (HMAs) as mainstay therapy advanced forms disease. this review, we summarize current understanding machinery regulation, discuss how arise contribute its then mode action HMAs